| Moderna to develop mRNA-based vaccine for shingles Feb 19th 2022, 07:11, by ruchika  New Delhi: Moderna Inc said on Friday it is developing three new vaccines based on the same technology used for its COVID-19 shot, including one for viral infection shingles.
The success of COVID-19 vaccines based on messenger RNA (mRNA) technology from Moderna and rival Pfizer has prompted efforts to use the novel technology in other vaccines and therapeutics targeted at hard-to-treat diseases. Pfizer is also developing an mRNA-based vaccine for shingles and expects to begin clinical trials in the second half of 2022. If successful, both companies will compete with GlaxoSmithKline's two-dose vaccine Shingrix, which was approved by the U.S. Food and Drug Administration in 2017. Shingles typically develops in older adults who were infected with chicken pox, or the varicella-zoster virus, when younger. It is characterized by a painful rash that generally clears up within a month. Read also: Moderna bags full USFDA nod for COVID vaccine Spikevax Moderna's shingles vaccine is being developed to target the varicella-zoster virus. The company is also developing a cancer vaccine and a shot against the herpes simplex virus-2, which causes genital herpes, a sexually transmitted disease. Read also: Omicron-specific booster could be ready by August: Moderna CEO |
